BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,373 | -33.2% | 11,917 | -33.6% | 0.00% | – |
| Q2 2023 | $126,262 | -0.7% | 17,935 | +17.6% | 0.00% | – |
| Q1 2023 | $127,160 | -9.4% | 15,247 | +24.8% | 0.00% | – |
| Q4 2022 | $140,286 | +15.0% | 12,220 | +26.0% | 0.00% | – |
| Q3 2022 | $122,000 | +139.2% | 9,700 | +102.8% | 0.00% | – |
| Q2 2022 | $51,000 | -13.6% | 4,783 | +30.3% | 0.00% | – |
| Q1 2022 | $59,000 | -16.9% | 3,672 | -29.1% | 0.00% | – |
| Q4 2021 | $71,000 | +7000.0% | 5,178 | +5718.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 89 | -13.6% | 0.00% | – |
| Q4 2017 | $1,000 | 0.0% | 103 | -65.8% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 301 | -3.8% | 0.00% | – |
| Q1 2016 | $1,000 | 0.0% | 313 | +172.2% | 0.00% | – |
| Q4 2015 | $1,000 | – | 115 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |